21st International AIDS Conference (AIDS 2016) Conference Review

In this Review:

Once- vs twice-daily raltegravir for initial HIV therapy
t HIV testing, same-day ART improves retention and viral suppression
Monthly vaginal ring offers good HIV-1 protection
On-demand PrEP: high efficacy confirmed
Mapping population viral load and HIV incidence
Universal test and treat: No reduction in HIV incidence
Postpartum ART must be continued
Free, home-based HIV testing increases GBM testing rates
Dolutegravir + lamivudine: suitable for ART-naïve patients?
Consider dolutegravir/abacavir/ lamivudine in ART-naïve women

Please login below to download this issue (PDF)